Latest Safety News

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.

Simble Solutions has acquired exclusive rights to a cutting-edge 3D zinc oxide nanosensor technology and completed a $2.5 million placement, positioning itself to expand its IoT platform into new safety and environmental monitoring markets.

Metallium Limited has initiated commissioning at its Texas Technology Campus following a successful first chlorine flash using its proprietary Flash Joule Heating technology, marking a significant step toward commercial operations.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Austral Gold has inked major mining service agreements to advance open pit operations at its Casposo Mine, aligning with its 2026 production targets. Early production is on track, underpinning confidence in the company’s growth trajectory.

Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

Renascor Resources has completed major equipment installation and begun commissioning at its Australian Government co-funded Purified Spherical Graphite demonstration facility, marking a pivotal step in its sustainable battery anode materials strategy.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.